Stabilizing endothelium of donor hearts with fusogenic liposomes reduces myocardial injury and dysfunction

Abstract Background Myocardial injury after heart transplantation is a consequence of pathophysiologic events initiated by local ischemia/reperfusion injury that is further aggravated by the inflammatory response due to blood exposure to the pump’s artificial surfaces during cardiopulmonary bypass....

Full description

Saved in:
Bibliographic Details
Published inThe Journal of surgical research Vol. 182; no. 2; pp. 331 - 338
Main Authors Fensterer, Tathyana F., MD, PhD, Keeling, W. Brent, MD, Patibandla, Phani K., PhD, Pushpakumar, Sathnur, MD, PhD, Perez-Abadia, Gustavo, MD, Bauer, Philip, PhD, Soni, Chirag V., PhD, Anderson, Gary L., PhD, Maldonado, Claudio, PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.06.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background Myocardial injury after heart transplantation is a consequence of pathophysiologic events initiated by local ischemia/reperfusion injury that is further aggravated by the inflammatory response due to blood exposure to the pump’s artificial surfaces during cardiopulmonary bypass. The purpose of the present study was to determine the effectiveness of fusogenic lipid vesicles (FLVs) in enhancing the cardioprotective effect of St. Thomas organ preservation solution (ST). We hypothesized that donor hearts preserved with ST+FLVs will stabilize the endothelium during reperfusion, which, in turn, will reduce both endothelial barrier dysfunction and myocardial damage. Methods To examine the effect of ST+FLVs therapy in vitro, C3b deposition and adhesion molecule expression studies were performed on human umbilical vein endothelial cells challenged with plastic contact-activated plasma. To assess the therapy in vivo, a cervical heterotopic working heart transplantation model in rats was used. Donor hearts were preserved for 1 h at 27°C (15 min) and 4°C (45 min) and, after transplantation, were followed up for 2 h. Left ventricular function and the blood cardiac troponin I levels were quantified. Results Human umbilical vein endothelial cells treated with ST+FLVs had reduced C3b deposition and expression of adhesion molecules compared with ST alone ( P < 0.05). Donor hearts receiving ST+FLVs therapy had reduced left ventricular dysfunction and cardiac troponin I compared with ST alone. Conclusions We concluded that FLVs enhanced the cardioprotective effect of ST and reduced postischemic left ventricular dysfunction and myocardial damage. The mechanism of protection appears to be associated with the stabilization of endothelial cell membranes owing to incorporation of FLV-derived lipids.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2012.10.022